| Pharmacological management of benign prostatic hypertrophy with phosphodiesterase-5 inhibitors. | |
| | |
MedLine Citation:
|
PMID: 20017412 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Benign prostatic hypertrophy (BPH) and its associated lower urinary-tract symptoms (LUTS) commonly result in a significant decrease in the quality of life (QOL) of aging men. Although several safe and effective medications are currently available for the management of this disease, newly emerging research has focused on the exploration of unconventional pharmacological therapy. In particular, multiple clinical trials published within the past two years have explored the use of phosphodiesterase-5 (PDE-5) inhibitors for the alleviation of LUTS secondary to BPH. Although this class of medication has traditionally been used in men with erectile dysfunction (ED), the preliminary results from these studies have offered promising evidence for use of PDE-5 inhibitors in BPH. |
| | |
Authors:
|
Sara Govonlu; Fae G Wooding |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists Volume: 24 ISSN: 0888-5109 ISO Abbreviation: Consult Pharm Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-12-18 Completed Date: 2010-01-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9013983 Medline TA: Consult Pharm Country: United States |
Other Details:
|
Languages: eng Pagination: 769-71 Citation Subset: IM |
Affiliation:
|
CVS Pharmacy, Needham, Massachusetts. USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Clinical Trials as Topic Cyclic Nucleotide Phosphodiesterases, Type 5 / antagonists & inhibitors* Humans Male Middle Aged Phosphodiesterase Inhibitors / therapeutic use* Prostatic Hyperplasia / drug therapy*, physiopathology Quality of Life |
| Chemical | |
Reg. No./Substance:
|
0/Phosphodiesterase Inhibitors; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Assessment of the use of xerogenic medications for chronic medical and dental conditions among adult...
Next Document: Genotoxicity of 1,3-butadiene and its epoxy intermediates.